Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Efficacy of GW5282 in Participants With Advanced Solid Tumors (BEI-DOU2)

NCT07328217 is registered in ClinicalTrials.gov with Dizal Pharmaceuticals as lead sponsor.

NCT NCT07328217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07328217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Efficacy of GW5282 in Participants With Advanced Solid Tumors (BEI-DOU2)
Lead sponsor
Dizal Pharmaceuticals
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 29, 2026
Completion date
June 30, 2029
Enrollment
203 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors